21:40 , Jan 3, 2018 |  BC Innovations  |  Product R&D

Expanding small molecule horizons

With a platform boasting more than a decade of preclinical rigor and $55.3 million in series A funding, Expansion Therapeutics Inc. is the latest company to step into the RNA-binding small molecule arena. The newco...
17:57 , Sep 14, 2017 |  BC Innovations  |  Emerging Company Profile

RNA gets CRISPR

Two of the outstanding hurdles for CRISPR-based gene editing are the safety concerns of permanently changing the cell’s DNA and the efficacy limitations of relying on natural DNA repair mechanisms to fix the cuts. Locana...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Rethinking risk

Steve Edelson, Senior Editor   The second half does not contain the high-impact, sector-moving milestones seen in the first six months of the year, but investors still have at least 90 late-stage milestones from which...
07:00 , Apr 28, 2016 |  BC Innovations  |  Finance

Virtually biotechs

Harvard University 's $20 million licensing deal with Merck & Co. Inc in March for a preclinical cancer therapy brought in more cash in one swoop than the university's tech transfer office saw in all...
07:00 , Mar 14, 2016 |  BioCentury  |  Emerging Company Profile

AMO's CNS ammunition

AMO Pharma Ltd. is in-licensing therapies for rare genetic diseases with no treatment options, starting with two potentially disease-modifying candidates for fragile X syndrome and myotonic dystrophy type 1. The company's first candidate is AMO-01...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Company News

Columbia Laboratories, XenoGesis deal

Columbia Laboratories’ CRO subsidiary, Molecular Profiles Ltd. , partnered with XenoGesis to provide preclinical and formulation development services. XenoGesis will provide expertise in preclinical drug metabolism and pharmacokinetics ( DMPK ) to support Molecular Profiles’...
07:00 , Aug 11, 2014 |  BioCentury  |  Finance

Mining Quebec

An option deal with Roche (SIX:ROG; OTCQX:RHHBY) marks the first potential exit for early stage life science venture fund AmorChem and its in-house medicinal chemistry CRO, NuChem Therapeutics Inc. The deal gives Roche an option...
07:00 , Aug 4, 2014 |  BC Week In Review  |  Company News

Roche, AmorChem deal

Roche partnered with VC fund AmorChem to discover small molecules to treat myotonic muscular dystrophy type 1. Discovery will take place at AmorChem’s medicinal chemistry incubator NuChem Therapeutics Inc. using technology discovered by University of...
01:12 , Jul 30, 2014 |  BC Extra  |  Company News

Roche, AmorChem partner for myotonic muscular dystrophy

Roche (SIX:ROG; OTCQX:RHHBY) partnered with VC fund AmorChem L.P. (Montreal, Quebec) to discover small molecules to treat myotonic muscular dystrophy type 1. Discovery will take place at AmorChem's medicinal chemistry incubator NuChem Therapeutics Inc. using...
07:00 , Jul 24, 2014 |  BC Innovations  |  Targets & Mechanisms

Selecting CDK7

Selective inhibitors of cyclin dependent kinase s have been hard to develop because the active sites of many family members are so similar. Now, a Harvard Medical School team has found a cyclin dependent kinase...